Post-treatment survival rate of uterine corpus cancer patients

Abstract

Aim. To study the post-treatment survival of patients with uterine body cancer depending on a parity and the metabolic syndrome.

Material and methods. 218 patients with a proven diagnosis of uterine body cancer, who were examined and treated at the State Institution “Republican Oncological Research Center” of the MoHSP of RT, for the period from 2007 to 2019, participated in the study. All patients, depending on the parity, were divided into groups: multiparous (n=101), low-parous (n=84), and infertile (n=33). Survival rate was measured using the Kaplan-Meier curve comparison using the Cox F-test, and differences were considered statistically significant at p<0.05.

Results. An analysis of the overall cumulative post-treatment survival of uterine body cancer patients by the KaplanMeier method showed that 55% of patients are alive 60 months after the treatment, and 48% of patients after 85 months. Survival rates in the group of women with multiple births are better than in the group of women with few births (55% of women with multiple births and 45% of women with few births lived for 70 months). But these differences are not statistically significant (p>0.05). The lowest survival rates are observed in the group of low-birth-weight uterine body cancer patients with metabolic syndrome, and the best rates are in the group of multiparous patients without metabolic syndrome although the difference was not statistically significant (p>0.05).

Conclusion. The analysis of the survival of patients with uterine body cancer in the region of high birth rate using the Kaplan-Meier method showed that the survival of patients with uterine body cancer depends not only on the stage of the disease and methods of therapy but also on the parity and concomitant extragenital pathology, such as metabolic syndrome.